Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy

Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer cell Jg. 28; H. 1; S. 11
Hauptverfasser:	Kelderman, Sander, Schumacher, Ton N, Kvistborg, Pia
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 13.07.2015
Schlagworte:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use DNA Mismatch Repair Humans Neoplasms - drug therapy Neoplasms - metabolism Programmed Cell Death 1 Receptor - antagonists & inhibitors Tumor Microenvironment - drug effects
ISSN:	1878-3686, 1878-3686
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!